Abstract
Ribonucleotide reductase (RNR) catalyzes the reduction of ribonucleotides into deoxyribonucleotides, which are essential for DNA replication and cell division. RNR is especially abundant in proliferating cancer cells and is an increasingly popular target in anticancer research. We had previously reported that the experimental anticancer prodrug Laromustine inhibits the enzyme thioredoxin reductase (TrxR), which is involved in proper RNR activity. Laromustine has been used in clinical trials to treat patients with acute myelogenous leukemia and glioblastoma multiforme. In this study, we use a particular sample preparation method and HPLC coupled to high‐resolution time of flight mass spectrometry to quantify deoxyribonucledotide diphosphate pools in human cells. These experiments will allow us to assess changes in RNR activity from cultured human cancer cells in response to treatment with Laromustine. We hope to further elucidate the mechanism by which Laromustine kills cancer cells, possibly influencing the clinical applications of Laromustine or similar agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
